Prognostic value of T2* parameters of MR-perfusion in assessing the survival of patients with brain glioblastoma

The use of MR perfusion data as a prognostic marker is a promising but understudied area in neuro- oncology, which prompted this work. The object of the study were 47 patients: 26 women (55.3%) and 21 men (44.7%), aged 26-89 years, with a confirmed diagnosis of WHO Grade IV glioblastoma, examined and treated at the Federal State Budgetary Institution “Russian Scientific Center of Roentgenoradiology” in the period 2018-2021 y. In all patients before RT according to MRI data with T2* perfusion in the residual tumor the main perfusion parameters were determined and their relative values (rCBV; rCBF; rMTT) were calculated. Survival of patients depending on T2* perfusion parameters in the residual fragments of the primary tumor before RT was compared using a log-rank criterion. Kaplan-Meier method was used for survival analysis. Follow-up time ranged from 3 to 42 months. As a result, a definite trend was revealed in the form of a survival advantage in patients with signs of hypoperfusion in the residual tumor; thus, life expectancy was longer and the number of lethal outcomes was lower with relatively low MR perfusion values: rCBV ≤ 3.30, rCBF ≤ 2.02, rMTT ≤1.10. There was a positive correlation between low values of cerebral blood flow velocity rCBF and CHF.